Please ensure Javascript is enabled for purposes of website accessibility
Inicio > Productos > Anticuerpos > Biosimilares

Anti-Human IL-17A/F Heterodimer Reference Antibody (Afasevikumab, RUO) (HS856076)

Anti-Human IL-17A/F Heterodimer Reference Antibody (Afasevikumab, RUO)
Anti-Human IL-17A/F Heterodimer Reference Antibody (Afasevikumab, RUO)
Anti-Human IL-17A/F Heterodimer Reference Antibody (Afasevikumab, RUO)
Anti-Human IL-17A/F Heterodimer Reference Antibody (Afasevikumab, RUO)
Anti-Human IL-17A/F Heterodimer Reference Antibody (Afasevikumab, RUO)
Anti-Human IL-17A/F Heterodimer Reference Antibody (Afasevikumab, RUO)
Precio(USD):
Especificación:
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
Número:
Contáctenos
  • Vista general

  • Imágenes

  • Referencias

  • Datasheet

  • SDS

Vista general
Número de catálogoHS856076
Descripción
Research Grade Afasevikumab (HS856076) is a human monoclonal antibody detecting CTLA-8 in ELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable for Human.
Highlights
  • ●Multi-Application — Validated across multiple applications.
Reactividad de especiesHuman
AplicacionesELISA, Bioactivity: FCM, Functional assay, Research in vivo
Especie huéspedHuman
ClonalidadMonoclonal
IsotipoIgG1-kappa
Objetivo CTLA-8, CTLA8, Cytotoxic T-lymphocyte-associated antigen 8, IL-17, IL-17A, IL17, IL17A, Interleukin-17A, Cytokine ML-1, IL-17F, IL17F, Interleukin-17F
Nivel de endotoxinas < 10 EU/mg
Pureza >95% as determined by SDS-PAGE.
Purificación Protein A/G purified from cell culture supernatant.
Número de acceso Q16552, Q96PD4
Forma Liquid
Buffer de almacenamiento 0.01M PBS pH 7.4.

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Estabilidad y almacenamiento Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativosMCAF-5352A, MCAF5352A, NI-1401, RG-7624, RG7624, RO5553110, 1589503-30-9
FondoAfasevikumab, also known as RG7624, is a human antibody inhibitor for human interleukin 17A (IL17A) and interleukin 17F (IL17F). This drug was developed by Genentech and has been investigated in the study of the treatment of inflammation diseases like autoimmune disorders. In 2013, Genentech completed a phase Ib study for the treatment of autoimmune disorders in Canada. However, it had been discontinued in 2015. In 2016, researchers used afasevikumab to conduct a phase I clinical trials for the treatment of inflammation in USA with no specified.
• IL-17 and IL-17-producing cells in protection versus pathology., PMID:35790881
• The IL-17 Family of Cytokines in Health and Disease., PMID:30995505
• The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond., PMID:30127781
• Functional specialization of interleukin-17 family members., PMID:21349428
• Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease., PMID:31866067
• The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases., PMID:37600764
• The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis., PMID:30109481
• Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies., PMID:37373452
• Rhythmic IL-17 production by γδ T cells maintains adipose de novo lipogenesis., PMID:39478228
• Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation., PMID:29275332
Nota For research use only. Not suitable for clinical or therapeutic use.
Isotype Control Human IgG1 Recombinant Isotype Control Antibody (HyHEL-10) (HV080407)
Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)
Imágenes
  • Anti-Human IL-17A/F Heterodimer Reference Antibody (Afasevikumab, RUO)

    SEC-HPLC

    SEC-HPLC detection for Research Grade Afasevikumab.

  • Anti-Human IL-17A/F Heterodimer Reference Antibody (Afasevikumab, RUO)

    Bioactivity

    Detects IL17A in indirect ELISAs.

  • Anti-Human IL-17A/F Heterodimer Reference Antibody (Afasevikumab, RUO)

    SDS-PAGE

    SDS-PAGE for Research Grade Afasevikumab.

Referencias
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recomendación

Contáctenos para cotizaciones personalizadas, solicitudes en masa y cualquier otro problema.

Correo: [email protected]

Lista de distribuidores